Engineered immune cells take aim at autoimmune diseases
NCT ID NCT05459870
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether specially engineered immune cells, called CAR-T cells, can safely treat autoimmune diseases. The cells are designed to target and suppress B cells, which play a key role in many autoimmune conditions. The trial involves 30 adults and focuses on safety and how well the cells work.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 4SCAR T cells
- What this could lead to
- If successful, this approach could offer a new way to control autoimmune diseases by targeting the immune cells that drive them.
- What could go wrong
- This is an early-phase trial with only 30 participants, so results may not apply broadly. CAR-T therapy carries risks like severe immune reactions and infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen Geno-immune Medical Institute
RECRUITINGShenzhen, Guangdong, 518000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Strumming for the brain: could ukulele lessons sharpen minds in MS?
- Could music be medicine for the injured brain?
- Can engineered immune cells tame autoimmune disease?
- Blood test may spot hidden nerve damage behind chronic constipation
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Could a metabolic modulator help people with type 1 diabetes use insulin better?